Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3T: Tucatinib + Trastuzumab + TAS-102 in HER2+ mCRC
NCT05356897Phase 2Withdrawn
- Sponsor
- Academic and Community Cancer Research United
- Start
- Oct 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucatinib in metastatic colorectal cancer (mCRC), sponsored by Academic and Community Cancer Research United. Planned start Oct 2023; status: withdrawn.
02
Drugs
tucatinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05356897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05356897.